Regeneron Pharmaceuticals Inc. will offer a gene therapy that restored hearing for a small number of profoundly deaf children ...
Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key ...
Regeneron Pharmaceuticals posted first-quarter revenue and profit above Wall Street expectations, driven by strong sales of Dupixent and Libtayo despite pressure on Eylea. The company also announced a ...
The agency's decision is based on results from a clinical trial in which the treatment improved hearing in 80 percent of the ...
Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it ...
The FDA approved Regeneron's Otarmeni on April 23, making it the first gene therapy for inherited hearing loss — and ...
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under ...
Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns ...
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...
Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results